Targeting of ICAM-1 on vascular endothelium under static and shear stress conditions using a liposomal Gd-based MRI contrast agent

Paulis, Leonie E. M.; Jacobs, Igor; Akker, Nynke Ms Van den; Geelen, Tessa; Molin, Daniël; Starmans, Lucas W. E.; Nicolay, Klaas; Strijkers, Gustav J.

doi:10.1186/1477-3155-10-25

Cited by 69 publications

(45 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hydrophilic agents and drugs can be encapsulated in the inner core of the liposomes, while hydrophobic and amphiphilic molecules can be incorporated on to the liposome membrane. Additionally, controlled release (7, 9) in combination with liposome targeting (10-12) can be utilized to reduce unintended side effects of drugs by delivering the drug preferentially to the desired site. Liposomes have recently been used to deliver a high payload of various magnetic resonance agents either encapsulated or incorporated into the liposome membrane for relaxation and sensitivity enhancement (1, 13, 14).…”

Section: Introductionmentioning

confidence: 99%

Characterization of a lanthanide complex encapsulated with MRI contrast agents into liposomes for biosensor imaging of redundant deviation in shifts (BIRDS)

et al. 2014

View full text Add to dashboard Cite

Purposely-designed magnetic resonance imaging (MRI) probes encapsulated in liposomes, which alter contrast by their paramagnetic effect on longitudinal (T1) and transverse (T2) relaxation times of tissue water, hold promise for molecular imaging. However a challenge with liposomal MRI probes that are solely dependent on enhancement of water relaxation is lack of specific molecular readouts, especially in strong paramagnetic environments, thereby reducing the potential for monitoring disease treatment (e.g., cancer) beyond the generated MRI contrast. Previously it has been shown that molecular imaging with magnetic resonance is also possible by detecting the signal of non-exchangeable protons emanating from paramagnetic lanthanide complexes themselves (e.g., TmDOTP5−, which is a Tm3+-containing biosensor based on a macrocyclic chelate 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrakis(methylene phosphonate), DOTP5−) with a method called Biosensor Imaging of Redundant Deviation in Shifts (BIRDS). Here we show that BIRDS is useful for molecular imaging with probes like TmDOTP5− even when they are encapsulated inside liposomes with ultra-strong T1 and T2 contrast agents (e.g., Magnevist and Molday ION, respectively). We demonstrate that molecular readouts like pH and temperature determined from probes like TmDOTP5− are resilient, because sensitivity of the chemical shifts to the probe’s environment is not compromised by presence of other paramagnetic agents contained within the same nanocarrier milieu. Because high liposomal encapsulation efficiency allows for robust MRI contrast and signal amplification for BIRDS, nanoengineered liposomal probes containing both monomers like TmDOTP5− and paramagnetic contrast agents could allow high spatial resolution imaging of disease diagnosis (with MRI) and status monitoring (with BIRDS).

show abstract

Section: Introductionmentioning

confidence: 99%

Characterization of a lanthanide complex encapsulated with MRI contrast agents into liposomes for biosensor imaging of redundant deviation in shifts (BIRDS)

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Among the inhibitors tested, amiloride (which inhibits CAM endocytosis) showed the strongest inhibitory effect. Targeting efficiency of a multimodal N-succinimidyl S-acetylthioacetate (SATA) ICAM-1-conjugated liposomal contrast agent (163 AE 2 nm) to TNF-a activated ECs in a unidirectional flow system (m-Slide) has been studied by Paulis et al 88 Although higher levels of stress resulted in higher ICAM-1 expression, application of flow reduced the ability of the targeted liposomes to adhere to mouse endothelioma cells (bEnd.5) within the range of stresses studied (0, 0.25, and 0.5 Pa).…”

Section: Targeting Efficacy Of Particles To Endothelium Using Camsmentioning

confidence: 99%

Targeting cell adhesion molecules with nanoparticles using in vivo and flow-based in vitro models of atherosclerosis

Khodabandehlou

Masehi-Lano

Poon

et al. 2017

Exp Biol Med (Maywood)

View full text Add to dashboard Cite

Impact statementAs atherosclerosis remains the leading cause of death, there is an urgent need to develop better tools for treatment of the disease. The ability to improve current treatments relies on enhancing the accuracy of in vitro and in vivo atherosclerotic models. While in vivo models provide all the relevant testing parameters, variability between animals and among models used is a barrier to reproducible results and comparability of NP efficacy. In vitro cultures isolate cells into microenvironments that fail to take into account flow separation and shear stress, which are characteristics of atherosclerotic lesions. Flow-based in vitro models provide more physiologically relevant platforms, bridging the gap between in vivo and 2D in vitro models. This is the first review that presents recent advances regarding endothelial cell-targeting using adhesion molecules in light of in vivo and flow-based in vitro models, providing insights for future development of optimal strategies against atherosclerosis. AbstractAtherosclerosis is a leading cause of death worldwide; in addition to lipid dysfunction, chronic arterial wall inflammation is a key component of atherosclerosis. Techniques that target cell adhesion molecules, which are overexpressed during inflammation, are effective methods to detect and treat atherosclerosis. Specifically, research groups have identified vascular cell adhesion molecule-1, intercellular adhesion molecule-1, platelet endothelial cell adhesion molecule, and selectins (E-selectin and P-selectin) as correlated to atherogenesis. In this review, we discuss recent strategies both in vivo and in vitro that target cell adhesion molecules. First, we discuss peptide-based and antibody (Ab)-based nanoparticles utilized in vivo for diagnostic, therapeutic, and theranostic applications. Second, we discuss flow-based in vitro models that serve to reduce the traditional disadvantages of in vivo studies such as variability, time to develop the disease, and ethical burden, but preserve physiological relevance. The knowledge gained from these targeting studies can be translated into clinical solutions for improved detection, prevention, and treatment of atherosclerosis.

show abstract

“…These devices have been used to determine the effect of shear stress and the presence of leukocytes on binding of ICAM-1 targeted liposomes to endothelium. 308 Small, multi-channel flow chambers provide an increase in throughput. Ibidi ® -slides with 6 channels and 8-channel Cellix Vena8 Endothelial + ™ biochips have been used to assess NP-cell interactions under flow and Cellix VenaT4 ™ biochips can be used for assessing cell transmigration and invasion.…”

Section: Multicell Flow-based Assaysmentioning

confidence: 99%

Testing Nanoparticles for Angiogenesis-Related Disease: Charting the Fastest Route to the Clinic

Sarsons¹,

Tekrony²,

Yaehne³

et al. 2014

j biomed nanotechnol

View full text Add to dashboard Cite

Recently, nanoparticles (NPs) have been established as ideal drug delivery vehicles for treating cancer. This is due to the enhanced permeability and retention (EPR) effect that is a direct result of the angiogenic nature of the tumor tissue and its ability to sequester chemotherapeutics from healthy tissues. Ideal drug delivery nanocarriers will exploit the EPR effect, accumulate in the tumorous tissue, and be able to release the drugs at a high concentration where needed, thereby reducing undesirable side effects. In order to determine ideal NP qualities that enable drugs to be delivered in such a manner, extensive testing in biological systems is required. However, it is impractical to study new potential nanocarriers in humans or in mammalian models due to the potential adverse consequences, low throughput, and high cost. Simpler models would allow for higher throughput screening of nanocarrier vehicles. This review outlines the most recent advances in alternative model assays and their significance in testing NPs en route to the clinic. In decreasing complexity, we examine zebrafish embryos, the chorioallantoic membrane of the chicken embryo, multicell static and flow-based assays, and single cell assays for efficacy, accuracy and utility as predictors for human therapeutic outcomes.

show abstract

Targeting of ICAM-1 on vascular endothelium under static and shear stress conditions using a liposomal Gd-based MRI contrast agent

Cited by 69 publications

References 41 publications

Characterization of a lanthanide complex encapsulated with MRI contrast agents into liposomes for biosensor imaging of redundant deviation in shifts (BIRDS)

Characterization of a lanthanide complex encapsulated with MRI contrast agents into liposomes for biosensor imaging of redundant deviation in shifts (BIRDS)

Targeting cell adhesion molecules with nanoparticles using in vivo and flow-based in vitro models of atherosclerosis

Testing Nanoparticles for Angiogenesis-Related Disease: Charting the Fastest Route to the Clinic

Contact Info

Product

Resources

About